Tumors & Contrast Agents
Weekend Course
ORGANIZERS: Xiaozhi Cao, Shoko Hara, Harpreet Hyare, Kenichi Oishi, Katharina Schregel, Leon Janse van Rensburg, Wietske van der Zwaag
Sunday, 11 May 2025
310 (Lili-u Theater)
13:15 -
17:15
Moderators: Akifumi Hagiwara & Jingwen Yao
Skill Level: Basic to Advanced
Session Number: WE-26
No CME/CE Credit
Session Number: WE-26
Overview
In the field of brain, head, and neck tumors, MRI is an essential tool for all clinical settings, such as pre-treatment diagnosis and assessments of treatment response. This course focuses on the new classification system, pre-treatment diagnosis, treatment, and post-treatment response of brain, head, and neck tumors.
Target Audience
This course targets researchers who want to update their knowledge about the diagnosis and treatment of brain tumors, and researchers/clinicians who want to update their knowledge of advanced MRI for preoperative evaluation.
Educational Objectives
As a result of attending this course, participants should be able to:
• Summarize the latest knowledge in brain, head & neck tumors;
• Summarize preoperative diagnosis using advanced MRI; and
• Identify treatment changes of brain tumors observed in MRI
| 13:15 | | New WHO Classification System of Brain Tumors Katharina Wenger |
| 13:40 | | Imaging of Treatment Response of Brain Tumors Sahaja Acharya |
| 14:05 | | Update of WHO Head & Neck Tumors Classifications Hirofumi Kuno |
| 14:30 | | Break & Meet the Teachers |
| 14:55 | | Imaging of Brain Tumors Using Contrast Materials Rajan Jain |
| 15:20 | | Reduced Contrast Agent for Tumor Perfusion Evaluation Limin Zhou |
| 15:45 | | Non-Contrast Imaging for Tumor Evaluation Ante Zhu |
| 16:10 | | Treatments of Brain Tumors Manabu Kinoshita Keywords: Cross-organ: Cancer The 2021 WHO Classification of Tumors of the Central Nervous System (WHO2021 for CNS tumors) has incorporated molecular characteristics to enhance the diagnosis of CNS tumors. Consequently, treatment protocols are now significantly influenced by this molecular information. The standard treatment regimen includes surgical resection, radiation therapy, chemotherapy, and molecular-targeted agents. Additionally, tumor-treating field therapy is specifically indicated for glioblastoma. This lecture is designed to address the standard care treatment for glioblastoma, astrocytoma, and oligodendroglioma, which are the three primary adult CNS tumors. |